ClinicalTrials.gg
RecruitingNCT06041659Updated Feb 13, 2025

Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia

An observational study in Moyamoya Disease, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Beijing Tiantan Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
48
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, none of them phase 3. Moyamoya Disease · Beijing Tiantan Hospital.

Planned enrollment
11th of 11
48 · median 350
Started
2023
with 1 other
Observational
11 of 14
8 open now
Registered
7th of 14
by date

Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, this one is the 11th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2023, is one of 11 observational ones, and was the 7th registered.

Moyamoya Disease

62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.

Browse Moyamoya Disease studies →

Open to participants now

10 of the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 22 Moyamoya Disease studies recruiting now, 9 (41%) set no upper age limit and 10 (45%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

Moyamoya disease is characterized by progressive stenosis of the genesis of the distal internal carotid arteries bilaterally and progressive generation of compensatory pathological vascular networks at the basis cranii, and these pathological vasculature has poor vascular reactivity. Perioperative circulatory management of patients with smoky vessels to ensure perfusion of brain tissue and integrity of brain network during surgery to minimize postoperative impairment of neurological functions, including motor, sensory, emotional and cognitive functions, is the key point of perioperative circulatory management of moyamoya disease. Functional Magnetic Resonance Imaging (fMRI) has been routinely used in various cerebrovascular diseases to further evaluate cerebrovascular reserve and cerebral network connectivity. The purpose of this study is to observe the changes in cerebral blood flow, cerebral oxygen metabolism, cerebral oxygen metabolism rate, and cerebral network connectivity in adult patients with moyamoya disease in cerebral ischemia-sensitive areas under anesthesia to provide a basis for exploring anesthesia management to improve cognitive function and cerebral network connectivity in these patients.

03

Conditions studied

  • Moyamoya Disease

Browse trials for

Keywords

  • Moyamoya Disease
  • Cerebral Network
  • Cognitive Function
  • Anesthesia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

We plan to recruit consecutive patients with moyamoya disease who are to undergo direct or indirect revascularization surgery from August 2023 to December 2025 at Beijing Tiantan Hospital of Capital Medical University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with moyamoya disease scheduled for direct or indirect intracranial and extracranial revascularization surgery
  • Age between 18-65 years
  • Obtain written .

Exclusion criteria

Exclusion Criteria:

  • Patients with preoperative claustrophobia, sensory or motor aphasia that are unable to understand and cooperate with the examination
  • Preoperative cranial imaging suggesting cerebral infarction lesion diameter >15mm
  • Patients allergic to anesthetic drugs
  • Metal implants in the body
  • Undergoing other experimental drug or instrumentation trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
48 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Changes of brain functional network

    Time frame: Before sedation, after sedation and after maintenan the blood pressure at baseline 100%-120% for 15min

Secondary outcomes

  1. Postoperative delirium

    Time frame: Day1-5 after surgery

  2. Electroencephalogram changes

    Time frame: Before sedation, after sedation and after maintenan the blood pressure at baseline 100%-120% for 15min

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 18, 2023
StartActual
Oct 24, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06041659
Responsible party
Yuming Peng (Clinical Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Sep 18, 2023
Start date
Oct 24, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 13, 2025

Study contacts

Shu Li
Contact
lishu@bjtth.org
8613699223065
Shu Li
principal investigator · Beijing Tiantan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion